Citius Pharmaceuticals Files 8-K
Ticker: CTXR · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1506251
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: CTRS
TL;DR
CTRS filed an 8-K, check for updates.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on February 6, 2025, reporting other events and financial statements. The company, incorporated in Nevada, has its principal executive offices in Cranford, NJ. This filing does not contain specific transactional details or financial figures beyond the reporting date.
Why It Matters
This 8-K filing indicates that Citius Pharmaceuticals has made a regulatory submission, which could contain important updates about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, without immediate indication of significant financial changes or negative news.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- Cranford, NJ (location) — Principal executive offices
- February 6, 2025 (date) — Date of report
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as the items being reported, but the specific details are not provided in the header information.
When was this 8-K report filed?
The report was filed on February 6, 2025.
What is the principal business address of Citius Pharmaceuticals, Inc.?
The principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
In which state was Citius Pharmaceuticals, Inc. incorporated?
Citius Pharmaceuticals, Inc. was incorporated in Nevada.
What is the Commission File Number for Citius Pharmaceuticals, Inc.?
The Commission File Number is 001-38174.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-02-06 09:20:50
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea0230159-8k_citius.htm (8-K) — 25KB
- ea023015901ex99-1_citius.htm (EX-99.1) — 35KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- ex99-1_002.jpg (GRAPHIC) — 5KB
- 0001213900-25-010747.txt ( ) — 253KB
- ctxr-20250206.xsd (EX-101.SCH) — 3KB
- ctxr-20250206_lab.xml (EX-101.LAB) — 33KB
- ctxr-20250206_pre.xml (EX-101.PRE) — 22KB
- ea0230159-8k_citius_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On February 6, 2025, Citius Pharmaceuticals, Inc., and its oncology-focused subsidiary, Citius Oncology, Inc., issued a press release to announce that LYMPHIR (denileukin diftitox-cxdl) has been assigned a unique, permanent Healthcare Common Procedure Coding System J-code by the Centers for Medicare & Medicaid Services. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated February 6, 2025. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: February 6, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2